Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending…
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic…
Regen BioPharma Discovers Potential New Way to Improve Outcomes from Cancer Surgery Using Combination of Cannabidiol and NR2F6 Inhibition
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today data demonstrating its unique combination of NR2F6 inhibition together with…
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today filing of a US patent application covering a newly discovered synergy between…
Regen BioPharma, Inc. Responds to Fake News Release
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP), has received a number of inquiries regarding a potential reverse merger with another…
Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist…
Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6,…
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist,…
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have identified a series of small molecule drugs that inhibit NR2F6…
Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has identified a series of small molecule drugs that inhibit NR2F6. Regen’s screening process…